HPV Vaccinations & the Cancer We May Be Learning How to Prevent

Key Takeaway: The evidence for HPV vaccination is no longer only about preventing infection. It is showing fewer cases of cervical cancer and, in some populations, fewer deaths. For health plans, the opportunity is ensuring eligible members start and complete the vaccine series early enough for the strongest protection.

A 12-year-old begins the HPV vaccine series.

No illness to treat. No expensive drug to approve. No specialist on the other side of the appointment. The vaccine is designed to prevent infection with human papillomavirus, or HPV, the virus responsible for most cervical cancers.

She gets the first dose. Six to 12 months later she returns for the second, which completes the series. She goes home and grows up.

Years later, the result may appear as something that never happens: no abnormal biopsy, no cervical cancer diagnosis, no oncology treatment.

For the first time, researchers are beginning to see that absence at a population level.

In England, across the five years from 2020 through 2024, not one woman between the ages of 20 and 24 died of cervical cancer. Based on historical rates, roughly 23 deaths would have been expected.

There were none.

This finding is part of a larger pattern. Researchers estimate England's HPV vaccination program had prevented roughly 200 cervical cancer deaths by the end of 2024, and because those women are still young, the effect compounds as the cohorts age.

National Immunization Awareness Month usually produces a broad reminder to stay current. This year, there’s something more specific to say.

How Effective Is the HPV Vaccine at Preventing Cervical Cancer?

The English mortality data is the newest evidence, but years of research point the same direction.

In Scotland, researchers linked national vaccination, screening and cancer records for women born between 1988 and 1996. Among women vaccinated at age 12 or 13, no cases of invasive cervical cancer were recorded. Unvaccinated women in the same cohorts developed invasive cervical cancer at a rate of 8.4 per 100,000 person-years.

In the United States, cervical cancer incidence among women ages 20 to 31 fell 27% between the pre-vaccine and vaccine eras, from 5.1 to 3.7 per 100,000. The disease still accounts for an estimated 13,360 new cases and 4,320 deaths each year.

Why Age at HPV Vaccination Matters

The most important detail may be when the vaccine is given.

In the Scottish data, vaccination at ages 12 or 13 was associated with complete protection against invasive cervical cancer in that population. Effectiveness fell to 86% among girls vaccinated at 14 to 16, and to 39% among those vaccinated at 17 to 18.

The reason is straightforward. HPV vaccines prevent infection. They don't clear one that's already established.

Protection works best when it arrives first.

That means the difference between vaccination at 12 and vaccination at 17 can change the protection a member receives. The opportunity for maximum protection comes early, and it can be easy to miss if no one is tracking who has started the series, who has completed it and who is aging into a less effective window.

Why HPV Vaccine Series Completion Matters

Coverage alone doesn't guarantee protection. HPV vaccination requires a series, with the number of doses depending on the age it begins. That creates another place prevention can break down.

In 2024, 79.1% of U.S. adolescent girls had received a first dose of HPV vaccine. Only 64.3% were up to date on the full series. Prevention requires all of it, delivered on schedule. A first dose is a start, not a safeguard—and recording a first dose is easy. Noticing that the second never arrived is harder, particularly when the two are given in different places.

A member may receive one dose in a pediatrician's office and another at a retail pharmacy. Records sit in different systems. A family changes providers. A reminder never arrives. Missed doses rarely announce themselves.

What Health Plans Should Ask About HPV Vaccination

Vaccines rarely dominate pharmacy strategy conversations. No six-figure price tags, no specialty trend surprises. That makes them easy to treat as passive: cover the dose and assume the job is done.

The HPV evidence suggests otherwise. It also suggests a short list of questions worth asking.

• How many eligible members start the series, and how many finish it?
• Does anything in the benefit design make the second dose harder to get than the first?
• Can a member's doses be seen together, wherever they were given?
• Is the adolescent window being treated as a clinical deadline rather than an indefinite opportunity?
• Are there clinical programs available to support uptake of vaccines?

None of these require a new program to answer. They require knowing what the current benefit can and cannot see.

Provider engagement matters too. In one meta-analysis, 24% of patients initiated HPV vaccination without a provider recommendation. With one, 60% did.

Sometimes the most powerful clinical protection isn't a new therapy. It's making sure an existing one reaches the right person at the right time.

Prevention a Benefit Can Actually See

For years, the case for HPV vaccination rested on what researchers expected would happen. Now the evidence is catching up. Fewer young women are developing cervical cancer, and in England, researchers are measuring something more consequential: fewer deaths.

That changes the question for benefit leaders. It's no longer whether the vaccine works. It's whether the benefit is built to make that protection real.

Somewhere in a health plan population today is a 12-year-old whose future cancer risk may be shaped by a few decisions that seem routine in the moment: whether the vaccine is recommended, whether the series is completed and whether it happens early enough to matter most.

That's the kind of prevention a benefit should be built to see.

FAQs

Is the HPV vaccine covered under the pharmacy benefit or the medical benefit?

It depends on the plan and where the dose is given. A vaccine administered in a physician's office is typically billed to the medical benefit, while one given at a retail pharmacy may run through the pharmacy benefit. Many plans allow both, which is why a single member's dose history can end up split across two claim systems.

Is the HPV vaccine covered without a copay?

For most non-grandfathered private plans, yes. The Affordable Care Act requires coverage of immunizations recommended by the Advisory Committee on Immunization Practices without cost sharing, generally when delivered by an in-network provider. Site of care and network status can still create out-of-pocket exposure, which is worth confirming against actual plan documents.

How many doses of the HPV vaccine are needed?

It depends on the age at which the series begins. Adolescents starting between ages 9 and 14 receive two doses, six to 12 months apart. Anyone starting at 15 or older receives three doses over roughly six months, as do immunocompromised patients aged 9 through 26. Earlier vaccination means fewer doses and stronger protection.

At what age is the HPV vaccine most effective?

Earlier is substantially better. CDC recommends routine vaccination at ages 11 to 12, and it can begin at 9. In Scottish national data, girls vaccinated at 12 or 13 had no recorded cases of invasive cervical cancer. Effectiveness fell to 86% among those vaccinated at 14 to 16, and to 39% at 17 to 18.

How can a health plan tell whether members are completing the HPV vaccine series?

It’s harder than it sounds. Doses given across pediatric offices, retail pharmacies and school-based programs can land in different systems, so a plan may see part of a series and read it as complete or as never started. Measuring completion rather than initiation requires looking across medical and pharmacy claims together.

Do women who received the HPV vaccine still need cervical cancer screening?

Yes. Current vaccines protect against most oncogenic HPV types but not all of them, estimated at around 85% of HPV-positive invasive cervical cancers in the Scottish population studied. Vaccination substantially reduces risk without eliminating it, so screening remains part of care for vaccinated patients.